 <h1>Bremelanotide Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to bremelanotide: subcutaneous solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, bremelanotide may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking bremelanotide:</p><p>
<i>More common</i>
</p><ul>
<li>Nausea</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Vomiting</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Blurred vision</li>
<li>dizziness</li>
<li>headache</li>
<li>nervousness</li>
<li>pounding in the ears</li>
<li>slow or fast heartbeat</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Dark urine</li>
<li>general tiredness and weakness</li>
<li>light-colored stools</li>
<li>upper right abdominal pain</li>
<li>yellow eyes and skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of bremelanotide may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site</li>
<li>feeling of warmth</li>
<li>redness of the face, neck, arms, and occasionally the upper chest</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Aching or discomfort in the lower legs or sensation of crawling in the legs</li>
<li>arm or leg pain</li>
<li>burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings</li>
<li>cough</li>
<li>darkening of the face, gums, or breasts</li>
<li>diarrhea</li>
<li>difficulty in moving</li>
<li>joint pain or swelling</li>
<li>muscle pains, cramps, or stiffness</li>
<li>runny or stuffy nose</li>
<li>stomach pain</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Chills</li>
<li>fever</li>
<li>general feeling of discomfort or illness</li>
<li>loss of appetite</li>
<li>shivering</li>
<li>sore throat</li>
<li>sweating</li>
<li>trouble sleeping</li>
</ul><p>
<!-- end subcutaneous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to bremelanotide: subcutaneous solution</i></p><h3>General</h3><p>The more commonly reported adverse reactions have included nausea, flushing, injection site reactions, headache, and vomiting.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Results of ambulatory blood pressure (BP) monitoring (n=127) showed a mean increase of 1.9 mmHg in daytime systolic BP and 1.7 mmHg in daytime diastolic BP after 8 days of dosing.  Increases were transient with a mean peak increase of 2.8 mmHg in systolic BP occurring between 4- and 8-hours post-dose and a mean peak increase in diastolic blood pressure of 2.7 mmHg occurring at 0 to 4 hours post-dose.  A mean transient decrease in heart rate of 0.5 beats per minute accompanied these transient increases in BP.  At 12 to 24 hours post-dose, BP values were similar to pre-dose values.</p><p><b>Very common</b> (10% or more): Flushing (20.3%) </p>
<p><b>Common</b> (1% to 10%): Hot flush </p>
<p><b>Frequency not reported</b>: Transient blood pressure increases, decreased heart rate</p><h3>Gastrointestinal</h3><p>In clinical trials, nausea was reported in 40% of patients (vs 1% placebo); median onset 1 hour and duration 2 hours.  The incidence was highest with the first dose and declined with subsequent doses.  Upper abdominal pain and diarrhea were reported in less than 2% of patients.</p><p><b>Very common</b> (10% or more): Nausea (40%) </p>
<p><b>Common</b> (1% to 10%): Vomiting</p>
<p><b>Frequency not reported</b>: Upper abdominal pain, diarrhea</p><h3>Dermatologic</h3><p>Focal hyperpigmentation involving face, gingiva and breasts was reported in 1% of patients who received up to 8 doses per month (placebo 0%).  In another clinical study, 38% of patients developed focal hyperpigmentation after receiving this drug daily for 8 days; an additional 14% developed new focal pigmentary changes upon continuing this drug for 8 more consecutive days.</p><p><b>Frequency not reported</b>: Focal skin hyperpigmentation</p><h3>Local</h3><p>Injection site reactions include injection site pain, unspecified injection site reactions, erythema, hematoma, pruritus, hemorrhage, bruising, paresthesia and hypoesthesia.</p><p><b>Very common</b> (10% or more): Injection site reactions (13.2%)</p><h3>Musculoskeletal</h3><p><b>Frequency not reported</b>: Myalgia, arthralgia, extremity pain, restless leg syndrome, increased creatine phosphokinase</p><p>Myalgia, arthralgia, restless leg syndrome, increased creatine phosphokinase, and pain in extremity were reported in less than 2% of patients.</p><h3>Hepatic</h3><p><b>Frequency not reported</b>: Acute hepatitis</p><p>One case of acute hepatitis has been reported in a patient receiving 10 doses of this drug over a 1-year period; serum transaminases exceeded 40 times the upper limit of normal (ULN), total bilirubin 6 x ULN, and alkaline phosphatase less than 2 x ULN.  Upon discontinuation, liver tests returned to normal after 4 months.</p><h3>Respiratory</h3><p>Rhinorrhea was reported in less than 2% of patients.</p><p><b>Common</b> (1% to 10%): Cough, nasal congestion </p>
<p><b>Frequency not reported</b>: Rhinorrhea</p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fatigue</p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (11.3%)</p>
<p><b>Common</b> (1% to 10%): Paraesthesia, dizziness</p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Vyleesi (bremelanotide)." AMAG Pharmaceuticals Inc, Lexington, MA. </p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>Vyleesi vs Addyi: What is the difference?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about bremelanotide</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>6 Reviews</li>
<li>Drug class: melanocortin receptor agonists</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Bremelanotide Subcutaneous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Vyleesi</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Hypoactive Sexual Desire Disorder</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to bremelanotide: subcutaneous solution</i></p><h3>General</h3><p>The more commonly reported adverse reactions have included nausea, flushing, injection site reactions, headache, and vomiting.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p>Results of ambulatory blood pressure (BP) monitoring (n=127) showed a mean increase of 1.9 mmHg in daytime systolic BP and 1.7 mmHg in daytime diastolic BP after 8 days of dosing.  Increases were transient with a mean peak increase of 2.8 mmHg in systolic BP occurring between 4- and 8-hours post-dose and a mean peak increase in diastolic blood pressure of 2.7 mmHg occurring at 0 to 4 hours post-dose.  A mean transient decrease in heart rate of 0.5 beats per minute accompanied these transient increases in BP.  At 12 to 24 hours post-dose, BP values were similar to pre-dose values.</p><p><b>Very common</b> (10% or more): Flushing (20.3%) </p><p><b>Common</b> (1% to 10%): Hot flush </p><p><b>Frequency not reported</b>: Transient blood pressure increases, decreased heart rate</p><h3>Gastrointestinal</h3><p>In clinical trials, nausea was reported in 40% of patients (vs 1% placebo); median onset 1 hour and duration 2 hours.  The incidence was highest with the first dose and declined with subsequent doses.  Upper abdominal pain and diarrhea were reported in less than 2% of patients.</p><p><b>Very common</b> (10% or more): Nausea (40%) </p><p><b>Common</b> (1% to 10%): Vomiting</p><p><b>Frequency not reported</b>: Upper abdominal pain, diarrhea</p><h3>Dermatologic</h3><p>Focal hyperpigmentation involving face, gingiva and breasts was reported in 1% of patients who received up to 8 doses per month (placebo 0%).  In another clinical study, 38% of patients developed focal hyperpigmentation after receiving this drug daily for 8 days; an additional 14% developed new focal pigmentary changes upon continuing this drug for 8 more consecutive days.</p><p><b>Frequency not reported</b>: Focal skin hyperpigmentation</p><h3>Local</h3><p>Injection site reactions include injection site pain, unspecified injection site reactions, erythema, hematoma, pruritus, hemorrhage, bruising, paresthesia and hypoesthesia.</p><p><b>Very common</b> (10% or more): Injection site reactions (13.2%)</p><h3>Musculoskeletal</h3><p><b>Frequency not reported</b>: Myalgia, arthralgia, extremity pain, restless leg syndrome, increased creatine phosphokinase</p><p>Myalgia, arthralgia, restless leg syndrome, increased creatine phosphokinase, and pain in extremity were reported in less than 2% of patients.</p><h3>Hepatic</h3><p><b>Frequency not reported</b>: Acute hepatitis</p><p>One case of acute hepatitis has been reported in a patient receiving 10 doses of this drug over a 1-year period; serum transaminases exceeded 40 times the upper limit of normal (ULN), total bilirubin 6 x ULN, and alkaline phosphatase less than 2 x ULN.  Upon discontinuation, liver tests returned to normal after 4 months.</p><h3>Respiratory</h3><p>Rhinorrhea was reported in less than 2% of patients.</p><p><b>Common</b> (1% to 10%): Cough, nasal congestion </p><p><b>Frequency not reported</b>: Rhinorrhea</p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fatigue</p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (11.3%)</p><p><b>Common</b> (1% to 10%): Paraesthesia, dizziness</p><p id="ref_1">1. "Product Information. Vyleesi (bremelanotide)." AMAG Pharmaceuticals Inc, Lexington, MA. </p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>Vyleesi vs Addyi: What is the difference?</li>
</ul><h2>More about bremelanotide</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>6 Reviews</li>
<li>Drug class: melanocortin receptor agonists</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Bremelanotide Subcutaneous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Hypoactive Sexual Desire Disorder</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>